Top Qs
Timeline
Chat
Perspective
Solangepras
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Solangepras (INN ; developmental code name CVN-424), or solengepras (USAN ), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease.[1][2][3][4] It is a small molecule and is taken by mouth.[1][4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents.[4] It is being developed by Cerevance.[1][2] As of October 2024, solangepras is in phase 3 clinical trials.[1][2]
Remove ads
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads